ABOUT THIS PROJECT
For too long, accessing catalytic funding has been a challenge for medicines discovery startups focused on areas of clinical unmet needs.
To combat this, we’re bringing together We Share’s innovative impact-driven revolving funding model with Medicines Discovery Catapult (MDC) Syndicate’s programme, enabling promising startups in the medicine discovery space access to long-term capital in the early phases of their growth.
Are you ready to scale your impact solution?

WHAT WE’RE LOOKING FOR
Projects must:
- Be focused on early-stage drug discovery (preclinical) with a maximum budget of €300,000. We
Share is happy to explore co-funding projects with other philanthropic funders; - Applicants must be able to demonstrate that funding for the total cost of the project has been
secured; - Have a maximum duration of 2 years from the date the grant is awarded;
- Clearly define the patient need that will be addressed and the impact they expect to achieve;
- Ideally have a lead asset, with proof-of-concept in animal models and/or disease linkage, solid IP
protection and comprehensive data packages, enabling the best chance of success to translate to
the clinic; - Be focused on advancing the preclinical development (prior to phase 1) of novel therapeutics that
have the potential to transform health outcomes for people with Cystic Fibrosis (CF), hearing
disorders or psychiatric disorders
FOCUS AREAS
MDC Syndicates are patient-focused partnerships that connect patient insights with industry know-how to progress promising ideas, positioning them for further development and investment. The Syndicate portfolio includes the CF AMR Syndicate, the Hearing Medicines Discovery Syndicate and the Psychiatry Consortium. We are looking for project proposals that will advance the development of small molecule, biologic, gene or cell-based therapeutics for the treatment of:

CYSTIC FIBROSIS INFECTIONS

HEARING LOSS & TINNITUS

PSYCHIATRIC DISORDERS
We’re looking for :
- early-stage medicines discovery startups across Europe that are hoping to create patient impact in any of our three focus areas
- projects at the preclinical stage that need funding to catalyse your R&D and get your company to the next stage in its lifecycle
- founders that want to be part of We Share’s pay-it-forward community, and pay forward their success to support future entrepreneurs
For more information, read our Grant Terms & Conditions, Application Terms & Conditions and Privacy Policy
HOW YOU BENEFIT
STARTUPS
- Access non-dilutive funding for early-stage patient-focused drug discovery
- Access patient and disease insights to support your project from MDC and its Syndicate programme
- Help us test an innovative funding model and tap into a new kind of philanthropic funding for medicines discovery
- Join the We Share community and pay your success forward to help future medicines discovery startups
FUNDING PARTNERS
- Bring more value to your philanthropic giving and fund solutions for unmet patient needs
- Revolve your grants and donations for health and contribute to SDG3 in a clear and financially sustainable way
- Help us test an innovative funding model and tap into a new kind of philanthropic funding for medicines discovery
- Be part of the development of a pioneering approach to fund medicine R&D
HOW IT WORKS

SDG FOCUS



QUESTIONS & QUERIES? CONTACT US

JESSICA LEE
Head of Patient-Focused Partnerships
Medicines Discovery Catapult

ELENI THEODOROU
Investor Relations & Strategy
We Share Forward